Search

Your search keyword '"van der Meer, Peter"' showing total 562 results
Start Over Author "van der Meer, Peter" Search Limiters Peer Reviewed
562 results on '"van der Meer, Peter"'

5. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure

Author

Solomon, Scott D., Ostrominski, John W., Wang, Xiaowen, Shah, Sanjiv J., Borlaug, Barry A., Butler, Javed, Davies, Melanie J., Kitzman, Dalane W., Verma, Subodh, Abildstrøm, Steen Z., Nygaard Einfeldt, Mette, Rasmussen, Søren, Abhayaratna, Walter P., Ahmed, Fozia Z., Ben-Gal, Tuvia, Chopra, Vijay, Ito, Hiroshi, Merkely, Bela, Núñez, Julio, Senni, Michele, van der Meer, Peter, Wolf, Dennis, Petrie, Mark C., and Kosiborod, Mikhail N.

Published
2024
Full Text
View/download PDF

9. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Author

Borlaug, Barry A., Kitzman, Dalane W., Davies, Melanie J., Rasmussen, Søren, Barros, Eric, Butler, Javed, Einfeldt, Mette Nygaard, Hovingh, G. Kees, Møller, Daniél Vega, Petrie, Mark C., Shah, Sanjiv J., Verma, Subodh, Abhayaratna, Walter, Ahmed, Fozia Z., Chopra, Vijay, Ezekowitz, Justin, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovsky, Vojtech, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, van der Meer, Peter, Von Lewinski, Dirk, Wolf, Dennis, and Kosiborod, Mikhail N.

Published
2023
Full Text
View/download PDF

11. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction

Author

Udell, Jacob A., Petrie, Mark C., Jones, W. Schuyler, Anker, Stefan D., Harrington, Josephine, Mattheus, Michaela, Seide, Svenja, Amir, Offer, Bahit, M. Cecilia, Bauersachs, Johann, Bayes-Genis, Antoni, Chen, Yundai, Chopra, Vijay K., Figtree, Gemma, Ge, Junbo, Goodman, Shaun G., Gotcheva, Nina, Goto, Shinya, Gasior, Tomasz, Jamal, Waheed, Januzzi, James L., Jeong, Myung Ho, Lopatin, Yuri, Lopes, Renato D., Merkely, Béla, Martinez-Traba, Monica, Parikh, Puja B., Parkhomenko, Alexander, Ponikowski, Piotr, Rossello, Xavier, Schou, Morten, Simic, Dragan, Steg, Philippe Gabriel, Szachniewicz, Joanna, van der Meer, Peter, Vinereanu, Dragos, Zieroth, Shelley, Brueckmann, Martina, Sumin, Mikhail, Bhatt, Deepak L., Hernandez, Adrian F., and Butler, Javed

Published
2024
Full Text
View/download PDF

12. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Author

Rosano, Giuseppe, Ponikowski, Piotr, Vitale, Cristiana, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Filippatos, Gerasimos, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Ruschitzka, Frank, Kumpeson, Vasuki, Goehring, Udo-Michael, van der Meer, Peter, and Jankowska, Ewa A.

Published
2023
Full Text
View/download PDF

15. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Author

Butler, Javed, Shah, Sanjiv J, Petrie, Mark C, Borlaug, Barry A, Abildstrøm, Steen Z, Davies, Melanie J, Hovingh, G Kees, Kitzman, Dalane W, Møller, Daniél Vega, Verma, Subodh, Einfeldt, Mette Nygaard, Lindegaard, Marie L, Rasmussen, Søren, Abhayaratna, Walter, Ahmed, Fozia Z, Ben-Gal, Tuvia, Chopra, Vijay, Ezekowitz, Justin A, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovský, Vojtěch, Merkely, Bela, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, Sharma, Kavita, van der Meer, Peter, Von Lewinski, Dirk, Wolf, Dennis, and Kosiborod, Mikhail N

Published
2024
Full Text
View/download PDF

17. Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: A study of the ESC EORP PPCM registry

Author

Sliwa, Karen, van der Meer, Peter, Viljoen, Charle, Jackson, Alice M., Petrie, Mark C., Mebazaa, Alexandre, Hilfiker-Kleiner, Denise, Maggioni, Aldo P., Laroche, Cecile, Regitz-Zagrosek, Vera, Tavazzi, Luigi, Roos-Hesselink, Jolien W., Hamdan, Righab, Frogoudaki, Alexandra, Ibrahim, Bassem, Farhan, Hasan Ali Farhan, Mbakwem, Amam, Seferovic, Petar, Böhm, Michael, Pieske, Burkert, Johnson, Mark R., and Bauersachs, Johann

Published
2024
Full Text
View/download PDF

18. Disruption of TUFT1, a Desmosome-Associated Protein, Causes Skin Fragility, Woolly Hair, and Palmoplantar Keratoderma

Author

Verkerk, Annemieke J.M.H., Andrei, Daniela, Vermeer, Mathilde C.S.C., Kramer, Duco, Schouten, Marloes, Arp, Pascal, Verlouw, Joost A.M., Pas, Hendri H., Meijer, Hillegonda J., van der Molen, Marije, Oberdorf-Maass, Silke, Nijenhuis, Miranda, Romero-Herrera, Pedro H., Hoes, Martijn F., Bremer, Jeroen, Slotman, Johan A., van den Akker, Peter C., Diercks, Gilles F.H., Giepmans, Ben N.G., Stoop, Hans, Saris, Jasper J., van den Ouweland, Ans M.W., Willemsen, Rob, Hublin, Jean-Jacques, Dean, M. Christopher, Hoogeboom, A. Jeannette M., Silljé, Herman H.W., Uitterlinden, André G., van der Meer, Peter, and Bolling, Maria C.

Published
2024
Full Text
View/download PDF

21. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review

Author

Salloum, Fadi N., Tocchetti, Carlo G., Ameri, Pietro, Ardehali, Hossein, Asnani, Aarti, de Boer, Rudolf A., Burridge, Paul, Cabrera, José-Ángel, de Castro, Javier, Córdoba, Raúl, Costa, Ambra, Dent, Susan, Engelbertsen, Daniel, Fernández-Velasco, María, Fradley, Mike, Fuster, José J., Galán-Arriola, Carlos, García-Lunar, Inés, Ghigo, Alessandra, González-Neira, Anna, Hirsch, Emilio, Ibáñez, Borja, Kitsis, Richard N., Konety, Suma, Lyon, Alexander R., Martin, Pilar, Mauro, Adolfo G., Mazo Vega, Manuel M., Meijers, Wouter C., Neilan, Tomas G., Rassaf, Tienush, Ricke-Hoch, Melanie, Sepulveda, Pilar, Thavendiranathan, Paaladinesh, van der Meer, Peter, Fuster, Valentin, Ky, Bonnie, and López-Fernández, Teresa

Published
2023
Full Text
View/download PDF

22. Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial

Author

Petrie, Mark C., Rouleau, Jean L., Claggett, Brian, Jering, Karola, van der Meer, Peter, Køber, Lars, Miao, Zi Michael, Lewis, Eldrin, Granger, Christopher, De Pasqulae, Carmine G., Mann, Douglas, Steg, Philippe Gabriel, Maggioni, Aldo, Amir, Offer, Lefkowitz, Marty, Braunwald, Eugene, Solomon, Scott D, McMurray, John J.V., and Pfeffer, Marc A.

Published
2024
Full Text
View/download PDF

23. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

Author

Butler, Javed, Abildstrøm, Steen Z., Borlaug, Barry A., Davies, Melanie J., Kitzman, Dalane W., Petrie, Mark C., Shah, Sanjiv J., Verma, Subodh, Abhayaratna, Walter P., Chopra, Vijay, Ezekowitz, Justin A., Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, van der Meer, Peter, von Lewinski, Dirk, Wolf, Dennis, Altschul, Rebecca L., Rasmussen, Søren, and Kosiborod, Mikhail N.

Published
2023
Full Text
View/download PDF

26. Career Insecurity and Burnout Complaints of Young Dutch Workers

Author

Wielers, Rudi, Hummel, Lisa, and van der Meer, Peter

Abstract

Burnout complaints among young workers in The Netherlands are high and increasing. Our research question is whether and how the high burn-out complaints of young workers in the Netherlands are associated with the employment relationships in the flexible labour market. We argue that especially an insecure career perspective contributes to burn-out complaints. Young workers in career jobs feel more insecure and this is a main reason why they have greater burnout complaints. We use the Netherlands Working Conditions Survey 2018 to test this argument. The analyses show that young workers in career jobs feel relatively insecure about their jobs and report a considerable higher level of burn-out complaints than student workers. Especially the workers in flexible career jobs suffer from insecurity and burnout complaints.

Published
2022
Full Text
View/download PDF

28. Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues

Author

Linders, Annet N., Dias, Itamar B., Ovchinnikova, Ekaterina S., Vermeer, Mathilde C.S.C., Hoes, Martijn F., Markousis Mavrogenis, George, Deiman, Frederik E., Arevalo Gomez, Karla F., Bliley, Jacqueline M., Nehme, Jamil, Vink, Aryan, Gietema, Jourik, de Boer, Rudolf A., Westenbrink, Daan, Sillje, Herman H.W., Hilfiker-Kleiner, Denise, van Laake, Linda W., Feinberg, Adam W., Demaria, Marco, Bomer, Nils, and van der Meer, Peter

Published
2023
Full Text
View/download PDF

29. Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy

Author

van der Schoot, Gabriela G.F., Ormel, Harm L., Westerink, Nico-Derk L., May, Anne M., Elias, Sjoerd G., Hummel, Yoran M., Lefrandt, Joop D., van der Meer, Peter, van Melle, Joost P., Poppema, Boelo J., Stel, Joyce M.A., van der Velden, Annette W.G., Vrieling, Aline H., Wempe, Johan B., ten Wolde, Marcel G., Nijland, Marcel, de Vries, Elisabeth G.E., Gietema, Jourik A., and Walenkamp, Annemiek M.E.

Published
2022
Full Text
View/download PDF

30. Heart failure with normal LVEF in BIOSTAT-CHF

Author

Baumhove, Lukas, Tromp, Jasper, Figarska, Sylwia, van Essen, Bart J., Anker, Stefan D., Dickstein, Kenneth, Cleland, John G., Lang, Chim C., Filippatos, Gerasimos, Ng, Leong L., Samani, Nilesh J., Metra, Marco, van Veldhuisen, Dirk J., Lam, Carolyn S.P., Voors, Adriaan A., and van der Meer, Peter

Published
2022
Full Text
View/download PDF

31. STICH3C: Rationale and Study Protocol

Author

Fremes, Stephen E., Marquis-Gravel, Guillaume, Gaudino, Mario F.L., Jolicoeur, E. Marc, Bédard, Sylvain, Masterson Creber, Ruth, Ruel, Marc, Vervoort, Dominique, Wijeysundera, Harindra C., Farkouh, Michael E., Rouleau, Jean-Lucien, Karkhanis, Reena, Arora, Rakesh, Graham, Michelle, Healey, Jeff, Howlett, Jonathan, Kiss, Alex, Ko, Dennis, Lee, Doug, McGillion, Michael, Sun, Louise, Swartz, Richard, Voisine, Pierre, Bax, Jeroen, Crea, Filippo, Doenst, Torsten, Jolly, Sanjit, Koeber, Lars V., Lamy, Andre, Lansky, Alexandra, van der Meer, Peter, Milojevic, Milan, Omerovic, Elmir, Petrie, Mark, Reid, Christopher, Sandner, Sigrid, Sousa-Uva, Miguel, Velazquez, Eric, Verma, Subodh, Stone, Gregg W., and Spertus., John

Published
2023
Full Text
View/download PDF

33. Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of Cardiology.

Author

Sliwa, Karen, Rakisheva, Amina, Viljoen, Charle, Pfeffer, Tobias, Simpson, Maggie, Jackson, Alice M., Petrie, Mark C., van der Meer, Peter, Al Farhan, Hasan, Jovanova, Silvana, Mbakwem, Amam, Sinagra, Gianfranco, Van Craenenbroeck, Emeline, Hoevelmann, Julian, Johnson, Mark R., Mindham, Richard, Chioncel, Ovidiu, Kahl, Kai G., Rosano, Giuseppe, and Tschöpe, Carsten

Subjects
CARDIOVASCULAR nurses, SOCIAL workers, HEART failure, EXTENDED families, QUALITY of life
Abstract

This statement focuses on the fact that women with peripartum cardiomyopathy (PPCM) have a substantial mortality and morbidity rate. Less than 50% of patients have full recovery of their cardiac function within 6 months of diagnosis. Also, patients with recovered cardiac function often suffer from comorbidities, such as hypertension or arrhythmias, which require long‐term treatment. This has major implications which extend beyond the life of the patient, as it may also substantially impact her family. Women with a new diagnosis of PPCM should be involved in the decision‐making processes regarding therapies, e.g. the recommendation to abstain from breastfeeding, or the use of cardiac implantable electronic devices. Women living with PPCM face the uncertainty of not knowing for some time whether their cardiac function will recover to allow them a near‐to‐normal life expectancy. This not only impacts their ability to work, which may have financial implications, but may also affect mental health and quality of life for the extended family. Women living with PPCM must be informed that a future pregnancy always carries a substantial risk and, in case of poor cardiac recovery, is associated with a high morbidity and mortality. Patients with PPCM are best managed by an interdisciplinary and multiprofessional approach including e.g. a cardiologist, a gynaecologist, nurses, a psychologist, and social workers. The scope of this document encompasses contemporary challenges and approaches for the management of women diagnosed with PPCM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE‐MI.

Author

Mc Causland, Finnian R., McGrath, Martina M., Claggett, Brian L., Barkoudah, Ebrahim, East, Cara, Fernandez, Alberto, Jering, Karola S., Lewis, Eldrin F., McMurray, John J.V., Mody, Freny Vaghaiwalla, Solomon, Scott D., Tokmakova, Mariya, van der Meer, Peter, Zhou, Yinong, and Pfeffer, Marc A.

Subjects
MYOCARDIAL infarction, SYSTOLIC blood pressure, GLOMERULAR filtration rate, CHRONIC kidney failure, KIDNEY physiology
Abstract

Aims: Pharmacologic blockade of neurohormonal pathways in patients with acute myocardial infarction (MI) can result in acute changes in biomarkers of kidney function. We evaluated the effect of sacubitril/valsartan versus ramipril on initial changes in serum creatinine and the association of these changes with longer‐term outcomes among participants in PARADISE‐MI. Methods and results: In this randomized, double‐blind, active‐controlled, event‐driven trial, 5661 patients with an acute MI were assigned to receive sacubitril/valsartan or ramipril, with no run‐in. The frequency of an initial pre‐specified increase in serum creatinine (≥26.5 or ≥44 μmol/L) from baseline to week 1 was compared between arms. Multivariable Cox regression models were fit to examine the association of acute changes in serum creatinine with the primary cardiovascular composite outcome (cardiovascular death, first heart failure hospitalization, or outpatient heart failure), all‐cause mortality, and longer‐term changes in estimated glomerular filtration rate (eGFR). An initial increase in serum creatinine ≥26.5 μmol/L occurred in 155 of 2604 (6.0%) patients assigned to sacubitril/valsartan and 120 of 2603 (4.6%) patients assigned to ramipril (odds ratio [OR] 1.32; 95% confidence interval [CI] 1.03–1.68). The corresponding numbers for an increase ≥44 μmol/L were 57 (2.2%) and 42 (1.6%), respectively (OR 1.37; 95% CI 0.92–2.05). A higher odds of increased serum creatinine ≥26.5 and ≥44 μmol/L for sacubitril/valsartan versus ramipril appeared to be restricted to patients who had a greater decline in systolic blood pressure over the same period (p‐interaction = 0.05 and 0.001, respectively). In multivariable analyses, neither an acute increase in serum creatinine ≥26.5 or ≥44 μmol/L was associated with a higher risk of cardiovascular outcomes, all‐cause mortality, or differences in longer‐term eGFR slope. Findings were similar across the randomized treatment arms (p‐interaction >0.6 for all). Conclusions: Following acute MI, patients assigned to sacubitril/valsartan had a higher frequency of initial increases in serum creatinine at 1 week, compared with ramipril. In adjusted models, initial increases in serum creatinine with either treatment were not associated with adverse cardiovascular outcomes or changes in longer‐term kidney function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after St-segment Elevation Myocardial Infarction (GIPS-IV) trial

Author

de Koning, Marie-Sophie LY, van Dorp, Paulien, Assa, Solmaz, Hartman, Minke HT, Voskuil, Michiel, Anthonio, Rutger L, Veen, Duco, Pundziute-Do Prado, Gabija, Leiner, Tim, van Goor, Harry, van der Meer, Peter, van Veldhuisen, Dirk J, Nijveldt, Robin, Lipsic, Erik, and van der Harst, Pim

Published
2022
Full Text
View/download PDF

38. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis

Author

Filippatos, Gerasimos, Ponikowski, Piotr, Farmakis, Dimitrios, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Rosano, Giuseppe, Ruschitzka, Frank, van der Meer, Peter, Wächter, Sandra, and Jankowska, Ewa A.

Published
2023
Full Text
View/download PDF

40. Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial.

Author

De Pasquale, Carmine G., Claggett, Brian, Jering, Karola, McMurray, John J. V., Mann, Douglas, Miao, Zi Michael, Granger, Christopher B., Køber, Lars, Maggioni, Aldo P., Rouleau, Jean-Lucien, Solomon, Scott D., Steg, Philippe Gabriel, van der Meer, Peter, Braunwald, Eugene, and Pfeffer, Marc A.

Published
2024
Full Text
View/download PDF

41. 404‐error "Disease not found": Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research.

Author

Esquivel Gaytan, Antonio, Bomer, Nils, Grote Beverborg, Niels, and van der Meer, Peter

Subjects
NOSOLOGY, HEART failure, CARDIAC research, MEDICAL practice, MULTIOMICS, DISEASE management
Abstract

The emergence of personalized medicine, facilitated by the progress in ‐omics technologies, has initiated a new era in medical diagnostics and treatment. This review examines the potential of ‐omics approaches in heart failure, a condition that has not yet fully capitalized on personalized strategies compared to other medical fields like cancer therapy. Here, we argue that integrating multi‐omics technology with systems medicine approaches could fundamentally transform heart failure management, moving away from the traditional paradigm of 'one size fits all'. Our review examines how omics can enhance understanding of heart failure's molecular foundations and contribute to a more comprehensive disease classification. We draw attention to the current state of medical practice that only relies on clinical evidence and a number of standard laboratory tests. At the same time, we propose a shift towards a universal approach that uses quantitative data from multi‐omics to unravel complex molecular interactions. The discussion centres around the potential of the transition as a means to enhance individual risk assessment and emphasizes management within clinical settings. While the use of omics in cardiovascular research is not recent, many past studies have focused only on a single omics approach. In order to achieve a better understanding of disease mechanisms, we explore more holistic approaches using genomics, transcriptomics, epigenomics, and proteomics. This review concludes with a call to action to adopt multi‐omics in clinical trials and practice to pave the way for more personalized disease management and more effective heart failure interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Renal function and natriuresis‐guided diuretic therapy – a pre‐specified analysis from the PUSH‐AHF trial.

Author

Damman, Kevin, Beldhuis, Iris E., van der Meer, Peter, Krikken, Jan A., Coster, Jenifer E., Nieuwland, Wybe, van Veldhuisen, Dirk J., Voors, Adriaan A., and ter Maaten, Jozine M.

Subjects
KIDNEY physiology, DIURETICS, GLOMERULAR filtration rate, HEART failure patients, EPIDERMAL growth factor receptors
Abstract

Aim: In a randomized controlled trial, we recently showed that a natriuresis‐guided diuretic approach improved natriuresis and diuresis in patients with acute heart failure (HF). In this pre‐specified analysis, we investigated the association between (worsening) renal function, outcomes and the effect of intensive natriuresis‐guided loop diuretic therapy as compared with standard of care. Methods and results: The Pragmatic Urinary Sodium‐based algoritHm in Acute Heart Failure (PUSH‐AHF) trial randomized patients to natriuresis‐guided diuretic therapy or standard of care. Serum creatinine and estimated glomerular filtration rate (eGFR) were assessed at fixed timepoints, and worsening renal function (WRF) was assessed at 72 h. The primary outcome was the interaction between randomized treatment allocation, baseline eGFR and the dual primary outcome of PUSH‐AHF: total natriuresis at 24 h and time to all‐cause mortality or HF rehospitalization at 180 days. In 309 patients, median baseline eGFR was 53 (35–73) ml/min/1.73 m2, and 58% had eGFR <60 ml/min/1.73 m2. Baseline eGFR did not significantly modify the treatment effect of natriuresis‐guided diuretic therapy on natriuresis at 24 h (p for interaction = 0.730). However, baseline eGFR significantly modified the effect on all‐cause mortality and HF rehospitalization (p for interaction = 0.017): the risk of this second primary outcome was lower in patients with lower eGFR who were randomized to the natriuresis‐guided group. In the natriuresis‐guided arm, eGFR decreased more (−11.0 vs. −6.91 ml/min/1.73 m2; p = 0.002) during the first 3 days, but this effect was attenuated at discharge (−10.3 vs. −8.69 ml/min/1.73 m2; p = 0.38). WRF was more frequently observed in patients randomized to natriuresis‐guided treatment, but was not associated with worse clinical outcomes. Conclusions: Natriuresis‐guided diuretic treatment improved diuresis and natriuresis irrespective of baseline eGFR and occurrence of WRF, was effective even in patients with low eGFR, and the observed effect on eGFR was transient and not associated with worse clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Distinct Pathological Pathways in Patients With Heart Failure and Diabetes

Author

Tromp, Jasper, Voors, Adriaan A., Sharma, Abhinav, Ferreira, João P., Ouwerkerk, Wouter, Hillege, Hans L., Gomez, Karla A., Dickstein, Kenneth, Anker, Stefan D., Metra, Marco, Lang, Chim C., Ng, Leong L., van der Harst, Pim, van Veldhuisen, Dirk J., van der Meer, Peter, Lam, Carolyn S.P., Zannad, Faiez, and Sama, Iziah E.

Published
2020
Full Text
View/download PDF

45. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy

Author

Grote Beverborg, Niels, Später, Daniela, Knöll, Ralph, Hidalgo, Alejandro, Yeh, Steve T., Elbeck, Zaher, Silljé, Herman H. W., Eijgenraam, Tim R., Siga, Humam, Zurek, Magdalena, Palmér, Malin, Pehrsson, Susanne, Albery, Tamsin, Bomer, Nils, Hoes, Martijn F., Boogerd, Cornelis J., Frisk, Michael, van Rooij, Eva, Damle, Sagar, Louch, William E., Wang, Qing-Dong, Fritsche-Danielson, Regina, Chien, Kenneth R., Hansson, Kenny M., Mullick, Adam E., de Boer, Rudolf A., and van der Meer, Peter

Published
2021
Full Text
View/download PDF

46. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

Author

Santema, Bernadet T., Chan, Michelle M. Y., Tromp, Jasper, Dokter, Martin, van der Wal, Haye H., Emmens, Johanna E., Takens, Janny, Samani, Nilesh J., Ng, Leong L., Lang, Chim C., van der Meer, Peter, ter Maaten, Jozine M., Damman, Kevin, Dickstein, Kenneth, Cleland, John G., Zannad, Faiez, Anker, Stefan D., Metra, Marco, van der Harst, Pim, de Boer, Rudolf A., van Veldhuisen, Dirk J., Rienstra, Michiel, Lam, Carolyn S. P., and Voors, Adriaan A.

Published
2020
Full Text
View/download PDF

50. Cardiac Function After Radiation Therapy for Breast Cancer

Author

van den Bogaard, Veerle A.B., van Luijk, Peter, Hummel, Yoran M., van der Meer, Peter, Schuit, Ewoud, Boerman, Liselotte M., Maass, Saskia W.M.C., Nauta, Jan F., Steggink, Lars C., Gietema, Jourik A., de Bock, Geertruida H., Berendsen, Annette J., Smit, Wilma G.J.M., Sijtsema, Nanna M., Kierkels, Roel G.J., Langendijk, Johannes A., Crijns, Anne P.G., and Maduro, John H.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results